- Home
- EDU vs SRRK Comparison
EDU vs SRRK Comparison
Compare EDU & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | SRRK |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | China | United States |
| Employees | 84111 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EDU | SRRK |
|---|---|---|
| Price | $58.81 | $47.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $62.80 | $56.17 |
| AVG Volume (30 Days) | 819.3K | ★ 1.0M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.83 | N/A |
| Revenue Next Year | $11.16 | $534.24 |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.25 | $27.07 |
| 52 Week High | $64.97 | $58.49 |
Technical Indicators
Market Signals| Indicator | EDU | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 76.03 | 39.11 |
| Support Level | $58.45 | $45.83 |
| Resistance Level | $61.28 | $48.23 |
| Average True Range (ATR) | 1.92 | 2.20 |
| MACD | 1.03 | -0.65 |
| Stochastic Oscillator | 85.89 | 5.15 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.